{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-016385","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.971807+00:00","generated_at":"2026-05-16T02:47:59.577684+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio advances CORDStrom in UK, secures FDA alignment for XPro1595 Alzheimer's program","bullets":["Submitted CORDStrom pre-submission package to UK MHRA for RDEB; targets full MAA filing mid-summer 2026.","FDA aligns on integrated Phase 2b/3 design for XPro1595 in early Alzheimer's; CDR-SB sole primary endpoint.","Phase 2b portion to enroll ~300 patients over 9 months; full program ~1,000 participants over 18 months.","Biomarker-driven enrichment strategy (hsCRP, ESR, HbA1c, APOE4) accepted; exploratory non-enriched cohort included.","CORDStrom also benefits from reauthorized Rare Pediatric Disease PRV program through 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-016385","json":"https://secwatch.observer/filing/0001213900-26-016385.json","markdown":"https://secwatch.observer/filing/0001213900-26-016385.md","text":"https://secwatch.observer/filing/0001213900-26-016385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026016385/0001213900-26-016385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026016385/ea0276865-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:47:59.577684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}